Introduction {#s1}
============

Systematic reviews (SRs) and meta-analyses (MAs) summarize large amounts of evidence and are a valuable tool for keeping clinicians up to date within their specialty [@pone.0113172-Oxman1], [@pone.0113172-Swingler1]. As with all research, however, the value of SRs/MAs depends on how the analyses are performed, the actual findings, and the clarity of reporting [@pone.0113172-Moher1]. If key information is reported poorly, the potential usefulness of the SRs/MAs is diminished.

Since 1987, numerous researchers have recognized the need to evaluate the quality of these types of reviews. For example, in 1987 Sacks and colleagues [@pone.0113172-Sacks1] evaluated reporting in SRs/MAs and found that it was inadequate. The Consolidated Standards of Reporting Trials (CONSORT) Group subsequently developed the Quality of Reporting of Meta-Analyses (QUOROM) statement to address suboptimal MA reporting. Ten years later, an updated QUOROM statement---entitled Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement---was developed and published [@pone.0113172-Moher1]. The PRISMA statement consists of a checklist of 27 study reporting items such as title, abstract, methods, results, discussion, and funding sources. The checklist is intended to guide authors of SRs/MAs to improve the consistency and quality of reporting.

Acupuncture, a traditional medicine technique, has been widely used in clinical practice for thousands of years in China and many western countries. The number of published SRs/MAs of acupuncture studies has increased considerably in recent years. As the transparency and completeness of SRs/MAs in many fields is still not optimal [@pone.0113172-Moher2]--[@pone.0113172-Delaney1], we examined how well SR/MA reporting standards have been followed in the field of acupuncture and compared adherence to these standards in acupuncture SRs/MAs published in three different types of journals/databases.

Methods {#s2}
=======

The protocol for this study was written in Chinese and has not been published. The study was not a classical systematic review, but we tried to report it according to PRISMA Checklist [@pone.0113172-Moher1] ([Text S1](#pone.0113172.s002){ref-type="supplementary-material"}).

Inclusion/exclusion criteria {#s2a}
----------------------------

We included all SRs or MAs of acupuncture published in Chinese journals, international journals, and the Cochrane Database of Systematic Reviews (CDSR) prior to 2014. The experimental group of SRs/MAs of acupuncture studies was also compared with a control group of SRs/MAs of studies of other interventions, such as herbal medicine, massage and western medicine. Participants: human in any conditions, not animal; Intervention: acupuncture; Comparisons: sham acupuncture or other interventions, such as herbal medicine, massage, western medicine, etc; Outcomes: no limitations; Study design: SRs/MAs. We excluded SRs/MAs that focused primarily on traditional Chinese medicine (TCM) other than acupuncture (e.g., herbal medicine, massage).

Search strategy {#s2b}
---------------

We comprehensively and systematically searched the following literature archives for SRs/MAs published prior to 2014: CDSR, PubMed, EMBASE, Web of Science, Chinese Biomedical Literature Database (CBM), the TCM database, Chinese Journal Full-text Database (CJFD), Chinese Scientific Journal Full-text Database (CSJD), and the Wanfang database. Databases were searched three times: on March 24, 2011 for all entries submitted prior to March 2011, on June 12, 2012 for all entries submitted prior to January 2012 and on January 11, 2014 for all entries submitted prior to 2014. The search terms "acupuncture", "needling", "ear acupuncture", "electroacupuncture", "electro-acupuncture", "acupuncture points", "acupressure", "moxibustion", and "acupoint" were used with the terms "systematic review" or "meta-analysis". The search strategy is presented in [Checklist S1](#pone.0113172.s001){ref-type="supplementary-material"}.

Screening {#s2c}
---------

The titles and abstracts of the studies were independently screened by at least two reviewers (Jiao Huang, Xu Zhao, or Rui Zhang) based on inclusion and exclusion criteria, and the full text of potentially suitable articles was retrieved for further assessment ([Text S2](#pone.0113172.s003){ref-type="supplementary-material"}).

Data extraction and analysis {#s2d}
----------------------------

Data were extracted independently by at least two reviewers (Rui Zhang, Jiao Huang, Xu Zhao, or Danlu Liu) in accordance with the PRISMA checklist and the assessment checklist for SRs/MAs of acupuncture studies developed for this study. Inconsistencies were subsequently resolved by discussion between the two reviewers or final decisions were made by the third principal investigator (Yali Liu). Data input utilized a standardized form and was done by trained data extractors (Wanting Sun, Pen Zhang, and Hua Cao). The form consisted of a general characteristics section (title, first author, funding source, study design, disease(s) examined, diagnostic criteria, intervention, and outcome) and a 27-item PRISMA information section (including title, abstract, introduction, method, results, discussion, and funding). Each item was assessed as "yes" if it was described in the paper or "no" if it was not ([Text S3](#pone.0113172.s004){ref-type="supplementary-material"}). Data were summarized with descriptive statistical analysis. For continuous data, the means ± SD was provided and one-way ANOVA was used. Data that followed a normal distribution were compared using the LSD- *t* test. Dichotomous data were summarized with descriptive statistical analysis (frequency, percentage). Pearson\'s *χ* ^2^ test and/or Fisher\'s exact test were used to assess differences in reporting among groups. *P* values less than 0.05 were considered significant. All statistical analyses were performed using Microsoft Excel (version 2007) and SPSS (version 13.0) software.

Results {#s3}
=======

Search {#s3a}
------

Our initial literature search identified 3993 potential SRs/MAs of acupuncture-related studies. After closer examination, 476 were chosen for inclusion in our analysis ([Text S4](#pone.0113172.s005){ref-type="supplementary-material"}). Of these, 203, 227, and 46 were published in Chinese journals, international journals, and CDSR, respectively. A flow chart of the literature search is shown in [Figure 1](#pone-0113172-g001){ref-type="fig"}.

![Flow chart of articles identified, included and excluded.](pone.0113172.g001){#pone-0113172-g001}

General characteristics {#s3b}
-----------------------

General characteristics of the SRs/MAs analyzed are summarized in [Table 1](#pone-0113172-t001){ref-type="table"}. The earliest acupuncture SRs/MAs in Chinese journals and international journals were published in 2002 and 1989, respectively. The number of acupuncture SRs/MAs in Chinese and international journals increased sharply after 2005, whereas the majority of acupuncture SRs/MAs in CDSR were published between 2008 and 2013 ([Figure 2](#pone-0113172-g002){ref-type="fig"}).

![The number of included SRs MAs on acupuncture.](pone.0113172.g002){#pone-0113172-g002}

10.1371/journal.pone.0113172.t001

###### Characteristics of included studies.

![](pone.0113172.t001){#pone-0113172-t001-1}

  Category                     Characteristic                                           Chinese journals n = 203                                                                 International journals n = 227                                                                      CDSRs n = 46
  --------------------- ----------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Title                       Systematic review                               123 (122+1[\*](#nt101){ref-type="table-fn"})                                                167 (124+43[\*](#nt101){ref-type="table-fn"})                                                                   NA
                                Meta analyses                                  66 (65+1[\*](#nt101){ref-type="table-fn"})                                                  78 (35+43[\*](#nt101){ref-type="table-fn"})                                                                    NA
  Author                      The first author                                                203 (China)                                                                62(China), 58(Korea), 39(England), 20(America)                                                  16(China), 10(England), 9(Australia)
  Funding source          Number of funded SRs/MAs                                            110 (54.19%)                                                                                 110(48.46%)                                                                                40(86.96%)
  Trial types                       RCTs                                                      193 (95.07%)                                                                                 215(94.71%)                                                                                46 (100.0%)
  Diseases                     The first three         Nervous system 45 (22.17%), Musculoskeletal system 40 (19.70%), Mental illness 32 (15.76%)   Nervous system 57 (25.11%), Musculoskeletal system 42 (18.50%), Mental illness 27(11.89%)   Musculoskeletal system 8 (17.39%), Nervous system 8 (17.39%), Mental illness 5 (10.87%)
  Diagnostic criteria    Western medicine (diseases)                                           74(36.45%)                                                                                  80(35.24%)                                                                                 19(41.30%)
                            Traditional medicine                                               44(21.67%)                                                                                   6(2.64%)                                                                                   0(0.00%)
  Intervention                                                                                203(100.00%)                                                                                227 (100.00%)                                                                                46 (100%)
  Outcome                 Including adverse effect                                            54 (26.60%)                                                                                 103 (45.37%)                                                                                33 (71.74%)
                          Including quality of life                                           25 (12.31%)                                                                                  45(19.82%)                                                                                 23 (50.00%)

\* Reported both "systematic review" and "meta-analysis".

Acupuncture SRs/MAs in Chinese journals were conducted entirely by Chinese authors, whereas those published in international journals tended to be multinational collaborations, with Chinese first authors being most prevalent (27.31%, 62/227). Chinese authors were also most prevalent first authors in CDSR studies (34.78%, 16/46). The percentage of published acupuncture SRs/MAs in Chinese journals, international journals, and the CDSR that reported at least one funding source was 54.19% (110/203), 50.66% (115/227), and 89.13% (41/46), respectively, and the maximum number of funding sources reported was 5, 3, and 7, respectively.

The majority of SRs/MAs (95.37%, 454/476) included at least one randomized controlled trial (RCT). Nervous system diseases, musculoskeletal system diseases, and mental illness were most frequently examined (23.11, 18.91 and 13.44%, respectively). Approximately 38% (180/476) of the SRs/MAs reported western diseases or TCM syndromes in their diagnostic criteria. All acupuncture SRs/MAs examined described the interventions in detail. 39.92% (190/476) and 19.54% (93/476) SRs/MAs included adverse events and quality-of-life in the outcome which were reported as primary and/or secondary outcomes.

PRISMA information reporting {#s3c}
----------------------------

Comparison of PRISMA reporting among the three types of journals/databases ([Table 2](#pone-0113172-t002){ref-type="table"})

10.1371/journal.pone.0113172.t002

###### Reporting of checklists for PRISMA statement.

![](pone.0113172.t002){#pone-0113172-t002-2}

  Category        Item             Total n = 476                       Chinese journals n = 203             International journals n = 227                   CDSRs n = 46                                     *P* value                     
  -------------- ------ ------------------------------------ --------------------------------------------- -------------------------------- ---------------------------------------------- ------------------------------------------------ -------
  Title            1                   Title                  390(90.70%)[@](#nt102){ref-type="table-fn"}            188(92.61%)             202(88.99%)[\*](#nt103){ref-type="table-fn"}                         NA                          NA
  Abstract         2             Structured summary                           446(93.70%)                            199(98.03%)             201(88.55%)[\*](#nt103){ref-type="table-fn"}    46(100.00%)[\#](#nt103){ref-type="table-fn"}    0.000
  Introduction     3                 Rationale                                380(79.83%)                            152(74.88%)                             182(80.18%)                    46(100.00%)[\*\#](#nt103){ref-type="table-fn"}   0.001
                   4                 Objective                                430(90.34%)                            160(78.82%)             225(99.12%)[\*](#nt103){ref-type="table-fn"}    45(97.83%)[\*](#nt103){ref-type="table-fn"}     0.000
  Methods          5         Protocol and registration                        60(12.61%)                               0(0.00%)                               18(7.93%)                     42(91.30%)[\*\#](#nt103){ref-type="table-fn"}    0.000
                   6            Eligibility criteria                          463(97.27%)                            196(96.55%)                             222(97.80%)                                      45(97.83%)                     0.710
                   7            Information sources                           440(92.44%)                            169(83.25%)             225(99.12%)[\*](#nt103){ref-type="table-fn"}                    46(100.00%)                     0.000
                   8                   Search                                 282(59.24%)                             87(42.86%)             156(68.72%)[\*](#nt103){ref-type="table-fn"}                     39(84.78%)                     0.000
                   9              Study selection                             342(71.85%)                            116(57.14%)             182(80.18%)[\*](#nt103){ref-type="table-fn"}    44(95.65%)[\*](#nt103){ref-type="table-fn"}     0.000
                   10         Data collection process                         411(86.34%)                            159(78.33%)             207(91.19%)[\*](#nt103){ref-type="table-fn"}                     45(97.83%)                     0.000
                   11                Data items                               270(56.72%)                             59(29.06%)             170(74.89%)[\*](#nt103){ref-type="table-fn"}    41(89.13%)[\*](#nt103){ref-type="table-fn"}     0.000
                   12    Risk of bias in individual studies                   384(80.67%)                            159(78.33%)                             182(80.18%)                                      43(93.48%)                     0.061
                   13             Summary measures                            387(81.30%)                            182(89.66%)             164(72.25%)[\*](#nt103){ref-type="table-fn"}                     41(89.13%)                     0.000
                   14           Synthesis of results                          402(84.45%)                            191(94.09%)             167(73.57%)[\*](#nt103){ref-type="table-fn"}    44(95.65%)[\#](#nt103){ref-type="table-fn"}     0.000
                   15       Risk of bias across studies                       155(32.56%)                             82(40.39%)             50(22.03%)[\*](#nt103){ref-type="table-fn"}    23(50.00%)[\*\#](#nt103){ref-type="table-fn"}    0.000
                   16           Additional analyses                           191(40.13%)                             77(37.93%)                              76(33.48%)                    38(82.61%)[\*\#](#nt103){ref-type="table-fn"}    0.000
  Results          17             Study selection                             430(90.34%)                            188(92.61%)                             197(86.78%)                                      45(97.83%)                     0.024
                   18          Study characteristics                          431(90.55%)                            176(86.70%)                             209(92.07%)                    46(100.00%)[\*\#](#nt103){ref-type="table-fn"}   0.012
                   19       Risk of bias within studies                       387(81.30%)                            155(76.35%)                             189(83.26%)                     43(93.48%)[\*](#nt103){ref-type="table-fn"}     0.016
                   20      Results of individual studies                      411(86.34%)                            196(96.55%)             172(75.77%)[\*](#nt103){ref-type="table-fn"}    43(93.48%)[\#](#nt103){ref-type="table-fn"}     0.000
                   21           Synthesis of results                          389(81.72%)                            192(94.58%)             156(68.72%)[\*](#nt103){ref-type="table-fn"}    41(89.13%)[\#](#nt103){ref-type="table-fn"}     0.000
                   22       Risk of bias across studies                       176(36.97%)                             91(44.83%)             66(29.07%)[\*](#nt103){ref-type="table-fn"}                      19(41.30%)                     0.003
                   23           Additional analysis                           165(34.66%)                             49(24.14%)                              75(33.04%)                    41(89.13%)[\*\#](#nt103){ref-type="table-fn"}    0.000
  Discussion       24           Summary of evidence                           432(90.76%)                            170(83.74%)             216(95.15%)[\*](#nt103){ref-type="table-fn"}    46(100.00%)[\*](#nt103){ref-type="table-fn"}    0.000
                   25               Limitations                               455(95.59%)                            188(92.61%)                             222(97.80%)                                      45(97.83%)                     0.024
                   26               Conclusions                               464(97.48%)                            193(95.07%)             226(99.56%)[\*](#nt103){ref-type="table-fn"}                     45(97.83%)                     0.012
  Funding          27                 Funding                                 324(68.07%)                            104(51.23%)             179(78.85%)[\*](#nt103){ref-type="table-fn"}    41(89.13%)[\*](#nt103){ref-type="table-fn"}     0.000

n = 430;

\* \# : there were statistical differences compared with Chinese journals and international journals, respectively.

Among 476 SRs/MAs, only 3 reported the information completely. By contrast, approximately 4.93% (1/203), 8.81% (2/227) and 0.00% (0/46) SRs/MAs reported less than 10 items on the checklist in Chinese journals, international journals, and CDSR, respectively. In general, the least frequently reported items (reported≤50%) in SRs/MAs were item 5 ("protocol and registration"), 15 and 22 ("risk of bias across studies"), and 16 and 23 ("additional analyses"). The remaining items on the checklist were adequately reported (i.e \>90%), with the items listed in [Table 2](#pone-0113172-t002){ref-type="table"} being especially well reported.

Comparison of PRISMA reporting before and after release of the PRISMA statement ([Table 3](#pone-0113172-t003){ref-type="table"})

10.1371/journal.pone.0113172.t003

###### The comparison for Reporting of checklists for SRs/MAs on PRISMA statement.

![](pone.0113172.t003){#pone-0113172-t003-3}

  Category        Item           ≦2009 year n = 186                       \>2009 year n = 290                                                  *P* value                                     SCI n = 204                 Non-SCI n = 272                                  *P* value                    
  -------------- ------ ------------------------------------ ---------------------------------------------- ------------------------------------------------------------------------------- ------------- --------------------------------------------- ---------------------------------------------- -------
  Title            1                   Title                  143(84.62%[\$](#nt104){ref-type="table-fn"})   247(95.00%[\#](#nt105){ref-type="table-fn"})[\*](#nt107){ref-type="table-fn"}      0.022      145(92.36%[&](#nt106){ref-type="table-fn"})   245(90.07%)[\*](#nt107){ref-type="table-fn"}   0.000
  Abstract         2             Structured summary                           171(91.94%)                                                     275(94.83%)                                       0.205                      188(92.16%)                                   258(94.85%)                    0.231
  Introduction     3                 Rationale                                113(60.75%)                                    268(92.41%)[\*](#nt107){ref-type="table-fn"}                       0.000                      172(84.31%)                   208(76.47%)[\*](#nt107){ref-type="table-fn"}   0.035
                   4                 Objective                                185(99.46%)                                    246(84.83%)[\*](#nt107){ref-type="table-fn"}                       0.000                      201(98.53%)                   229(84.19%)[\*](#nt107){ref-type="table-fn"}   0.000
  Methods          5         Protocol and registration                         24(12.90%)                                                     36(12.41%)                                        0.875                      56(27.45%)                     4(1.47%)[\*](#nt107){ref-type="table-fn"}     0.000
                   6            Eligibility criteria                          184(98.92%)                                                     279(96.54%)                                       0.076                      199(97.55%)                                   265(97.43%)                    0.933
                   7            Information sources                           179(96.24%)                                    261(90.00%)[\*](#nt107){ref-type="table-fn"}                       0.012                      202(99.02%)                   238(87.50%)[\*](#nt107){ref-type="table-fn"}   0.000
                   8                   Search                                 110(59.14%)                                                     172(59.31%)                                       0.971                      160(78.43%)                   122(44.85%)[\*](#nt107){ref-type="table-fn"}   0.000
                   9              Study selection                             124(66.67%)                                    224(75.68%)[\*](#nt107){ref-type="table-fn"}                       0.011                      173(84.80%)                   169(62.13%)[\*](#nt107){ref-type="table-fn"}   0.000
                   10         Data collection process                         165(88.71%)                                                     245(84.48%)                                       0.193                      187(91.67%)                   224(82.35%)[\*](#nt107){ref-type="table-fn"}   0.003
                   11                Data items                                98(52.69%)                                                     171(58.97%)                                       0.178                      153(75.00%)                   117(43.01%)[\*](#nt107){ref-type="table-fn"}   0.000
                   12    Risk of bias in individual studies                   143(76.88%)                                                     240(82.76%)                                       0.115                      172(84.31%)                                   212(77.94%)                    0.081
                   13             Summary measures                            141(75.81%)                                    246(84.83%)[\*](#nt107){ref-type="table-fn"}                       0.014                      160(78.43%)                                   227(83.46%)                    0.164
                   14           Synthesis of results                          147(79.03%)                                    255(87.93%)[\*](#nt107){ref-type="table-fn"}                       0.009                      162(79.41%)                   240(88.24%)[\*](#nt107){ref-type="table-fn"}   0.009
                   15       Risk of bias across studies                        39(20.97%)                                    118(40.69%)[\*](#nt107){ref-type="table-fn"}                       0.000                      66(32.35%)                                     90(33.09%)                    0.866
                   16           Additional analyses                            66(35.48%)                                                     125(43.10%)                                       0.098                      97(47.55%)                    95(34.93%)[\*](#nt107){ref-type="table-fn"}    0.005
  Results          17             Study selection                             162(87.10%)                                                     268(92.41%)                                       0.055                      183(89.71%)                                   247(90.81%)                    0.687
                   18          Study characteristics                          165(88.71%)                                                     266(91.72%)                                       0.273                      193(94.61%)                   238(87.50%)[\*](#nt107){ref-type="table-fn"}   0.009
                   19       Risk of bias within studies                       140(75.27%)                                    247(85.17%)[\*](#nt107){ref-type="table-fn"}                       0.007                      176(86.27%)                   212(77.94%)[\*](#nt107){ref-type="table-fn"}   0.020
                   20      Results of individual studies                      139(74.73%)                                    272(93.79%)[\*](#nt107){ref-type="table-fn"}                       0.000                      169(82.84%)                                   242(88.97%)                    0.054
                   21           Synthesis of results                          134(72.04%)                                    255(87.93%)[\*](#nt107){ref-type="table-fn"}                       0.000                      154(75.49%)                   235(86.40%)[\*](#nt107){ref-type="table-fn"}   0.002
                   22       Risk of bias across studies                        49(26.34%)                                    129(44.48%)[\*](#nt107){ref-type="table-fn"}                       0.000                      69(33.82%)                                    108(39.71%)                    0.189
                   23           Additional analysis                            57(30.65%)                                                     107(36.90%)                                       0.161                      94(46.08%)                    71(26.10%)[\*](#nt107){ref-type="table-fn"}    0.000
  Discussion       24           Summary of evidence                           182(97.85%)                                    249(85.86%)[\*](#nt107){ref-type="table-fn"}                       0.000                      193(94.61%)                   239(87.87%)[\*](#nt107){ref-type="table-fn"}   0.012
                   25               Limitations                               183(98.39%)                                    272(93.79%)[\*](#nt107){ref-type="table-fn"}                       0.017                      198(97.06%)                                   257(94.49%)                    0.176
                   26               Conclusions                               185(99.46%)                                    279(96.21%)[\*](#nt107){ref-type="table-fn"}                       0.033                      202(99.02%)                                   262 (96.32%)                   0.063
  Funding          27                 Funding                                 129(69.35%)                                                     200(68.97%)                                       0.929                      170(83.33%)                   154(56.62%)[\*](#nt107){ref-type="table-fn"}   0.000

n = 169,

n = 260,

n = 157.

\*: there were statistical differences compared with non-SCI journals/\>2009 y and SCI journals/2009 y, respectively.

We found no statistical difference (*P*\>0.05) for item 2 ("structured summary"), 5 ("protocol and registration"), 6 ("eligibility criteria"), 8 ("search"), 10 ("data collection process"), 11 ("data items"), 12 ("risk of bias in individual studies"), 16 ("additional analyses"), 17 ("study selection"), 18 ("study characteristics"), 23 ("additional analysis") and 27 ("funding") between SRs/MAs published prior to release of the PRISMA statement and those published after its release. Unfortunately, the rate of reporting of two items ("objective" and "information sources") had decreased in 2010--2013 compared with before 2010 (*P*\<0.001).

Comparison of PRISMA reporting in Science Citation Index (SCI) and non-SCI journals ([Table 3](#pone-0113172-t003){ref-type="table"})

We found that PRISMA reporting in SRs/MAs in SCI journals was more complete overall than in non-SCI journals, especially for items 4 ("objective"), 5 ("protocol and registration"), 7 ("information sources"), 8 ("search"), 9 ("study selection"), 11 ("data items"), 23 ("additional analysis"), and 27 ("funding") (*P*\<0.001).

Discussion {#s4}
==========

Over the last decade, numerous studies have assessed the quality of reporting in SRs/MAs by their compliance with assessment instruments such as the QUOROM and PRISMA statements [@pone.0113172-Willis1]--[@pone.0113172-Delaney3]. These studies focused predominantly on SRs/MAs covering diagnostic research and critical care. Although some quality assessment studies have looked at acupuncture SRs/MAs [@pone.0113172-Sood1]--[@pone.0113172-Lui1], they have focused mainly on methodological diversity in database searching, risk of bias, and heterogeneity in search strategies among CDSR. Our study compared reporting quality and PRISMA compliance in acupuncture SRs/MAs between different journal types.

We found that the five PRISMA items, namely "Protocol and registration", "Risk of bias across studies" (both in the [methods](#s2){ref-type="sec"} and [results](#s3){ref-type="sec"}), and "Additional analyses" (both in the [methods](#s2){ref-type="sec"} and [results](#s3){ref-type="sec"}) in the [methods](#s2){ref-type="sec"} and [results](#s3){ref-type="sec"}, are not frequently reported, indicating that the overall quality of reporting in acupuncture SRs/MAs is far from adequate. Compared with SRs/MAs published in CDSR, those in Chinese and international journals were of inferior reporting quality. One possible explanation for the limited compliance may be that journals have failed to incorporate the PRISMA statement into their instructions to authors about submitting SRs/MAs [@pone.0113172-Tao1]. We also found that SR/MA reporting was more complete in SCI journals than in non-SCI journals but that both require improvement in adherence to PRISMA standards.

Several studies have focused on the reporting quality of SRs/MAs covering the fields of TCM [@pone.0113172-Ma1], [@pone.0113172-Ma2], physical therapy [@pone.0113172-Padula1], orthopaedics [@pone.0113172-Gagnier1], and oral implantology [@pone.0113172-Kiriakou1] field, which showed that the reporting quality was indeed poor. Although differences exist between these results and those we repot here, the reporting of major items in the PRISMA statement was similar to what we found in our present study. Additional, Fleming PS et al. [@pone.0113172-Fleming1] found that the quality of reporting was considerably better in reviews published in CDSR (*P*\<0.001) than in non-CDSR.

Both the QUOROM and PRISMA statements encourage the use of specific terms in the titles of SRs/MAs, which help to identify these studies. Because of the special title format requirements of the CDSR, however, SRs/MAs published in this database cannot conform to the QUOROM/PRISMA recommendation.

Unequivocal descriptions of the scientific background and rationale for using acupuncture in the treatment of both western diseases and TCM syndromes provide the reader with a better understanding of the research context and rationale of SRs/MAs. In this respect, SRs/MAs in the CDSR were more explicit in their descriptions than those in international or Chinese journals.

The importance of protocol consistency and registration of SRs/MAs to the transparency of reporting is underscored by the fact that they are considered key aspects of the "reporting guidelines for systematic review protocols" in the international prospective register of systematic reviews (PROSPERO) [@pone.0113172-PROSPERO1], [@pone.0113172-Moher4]. We found that only SRs/MAs published in the CDSR provided protocol and registration details.

The PRISMA standards suggest that methodological details such as eligibility criteria, information sources, search strategies, study selection criteria, and data collection processes are necessary to judge the quality and accuracy of SRs/MAs. The majority of the SRs/MAs published in the CDSR adequately reported these items, whereas those published in Chinese and international journals did not. Eligibility criteria are an aspect of the PICOS criteria (participants, interventions, comparisons, outcomes, and study design) central to the PRISMA approach. We propose that it is equally important that search strategies be uniformly reported. Many international journals require information about search strategies in at least one database, and the flexibility of the CDSR layout allows reporting of search strategies for multiple databases. Chinese journals, however, rarely request search strategy information. There is also considerable need for more consistency in the databases obtain acupuncture studies. We propose that, AcuBriefs ([www.acubriefs.com](http://www.acubriefs.com)), AcuBase ([www.acubase.fr](http://www.acubase.fr)), Acudoc2 RCT ([www.acubriefs.com/](http://www.acubriefs.com/)), and the TCM database are the most systematic and comprehensive sources for acupuncture information. Chinese RCTs make up the highest proportion of primary studies included in acupuncture SRs/MAs. If methods for sequence generation, allocation concealment, and study blindness are not adequately described, low-quality studies [@pone.0113172-Wu1] may mislead reviewers.

We found that there is also considerable inconsistency in reporting of study selection criteria. For example, many primary studies on acupuncture report a random allocation design but are not specific enough for the reader to determine if they are actual RCTs. We propose that these uncertainties should be clarified by contacting the primary authors to determine the appropriateness of including the studies in the SRs/MAs. Because it has been suggested that only 6.8% of acupuncture efficacy studies published in Chinese journals are based on actual RCTs [@pone.0113172-Wu1], we strongly propose that authors of SRs/MAs verify this information prior to inclusion of studies.

Acupuncture is considered an alternative or complementary treatment to western medical interventions such as drugs and surgery, and it can be considered a separate specialty. Thus, SRs/MAs on acupuncture require not only compliance with general PRISMA reporting standards but also accurate reporting of acupuncture information. As a result, it is necessary to develop an extension of the PRISMA statement for acupuncture.

There are several limitations to our study. First, our analyses were limited to acupuncture-specific SRs/MAs and therefore may not be applicable to SRs/MAs in other fields. Second, our assessment process was not blinded, and therefore the outcomes may be influenced by publication date and other factors. Third, our assessment criteria (yes or no) did not allow partial information to be used. Fourth, our study focused primarily on acupuncture rather than other TCM. We failed to distinguish acupuncture from herbal medicine massage, or western medicine because individual SRs/MAs we included in our analysis often contained several control groups rather than one group.

In summary, SRs/MAs of acupuncture studies have not comprehensively reported the information recommended in the PRISMA statement. Our study underscores that, in addition to focusing on careful study design and performance, attention should be paid to comprehensive reporting standards when publishing SRs/MAs of acupuncture studies.
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